新锐医药(06108.HK)年度净亏扩大至6970万港元
格隆汇 4 月 1日丨新锐医药(06108.HK)发布公告,截至2020年12月31日止年度,集团录得收益约1.332亿港元,同比增加约12.3%;毛利约为1090万港元,同比减少约26.8%;公司拥有人应占净亏损约为6970万港元,同比增加约58.0%;基本每股亏损4.17港仙。
公告表示,本年度的总收益约同比增加约12.3%。医药产品分销及贸易的收益增加主要由于2019年临时暂停生产及出售该产品(1.0g)后,该产品(1.0g)已于2019年9月起恢复生产及出售。尽管该产品(1.0g)于本年度的销售表现有所改善,惟此分部业务因年内爆发Covid-19疫情,令集团的贸易活动及业务营运放缓而受到影响,加上年内中国部分地区新近推行药品集中采购文件,使该产品(1.0g)的平均售价下跌。本年度集团提供营销及推广服务所产生的收益与2019年相比保持稳定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.